BMO Capital Reiterates Pfizer (PFE) at Outperform, CLOVER Trial is Not Core but Substantial Attenuation in Infection is Encouraging Despite Endpoint Miss
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $76.00 price target on Pfizer (NYSE: PFE)The analyst quotes ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
